SUSAN GIESKE: Open Payments
NPI 1346908407 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,921 in 120 payments from 18 companies in 2025. Trend: 2023 $2,543 · 2024 $2,299 · 2025 $2,921
Food & beverage: $2,921
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $714 |
| GENZYME CORPORATION | 6 | $299 |
| Madrigal Pharmaceuticals | 8 | $259 |
| Gilead Sciences, Inc. | 11 | $253 |
| Janssen Biotech, Inc. | 9 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $211 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $186 |
| QOL Medical, LLC | 11 | $176 |
| Ardelyx, Inc. | 4 | $131 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
Products named: REZDIFFRA, DUPIXENT, TREMFYA, RINVOQ, XIFAXAN, Sucraid, ENTYVIO, SKYRIZI.
Industry payments across CO — which companies pay providers there.
